US pharmaceutical company Gilead buys MYR GmbH for 1.45 billion euros / MYR GmbH is licensee of the drug Hepcludex (Bulevirtide) developed by DZIF professor Dr Stephan Urban from Heidelberg / Hepcludex complements the portfolio of the US pharmaceutical giant with a drug against hepatitis D, which is urgently needed worldwide